Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Mato, AR; Roeker, LE; Lamanna, N; Allan, JN; Leslie, L; Pagel, JM; Patel, K; Osterborg, A; Wojenski, D; Kamdar, M; Huntington, SF; Davids, MS; Brown, JR; Antic, D; Jacobs, R; Ahn, IE; Pu, J; Isaac, KM; Barr, PM; Ujjani, CS; Geyer, MB; Berman, E; Zelenetz, AD; Malakhov, N; Furman, RR; Koropsak, M; Bailey, N; Hanson, L; Perini, GF; Ma, S; Ryan, CE; Wiestner, A; Portell, CA; Shadman, M; Chong, EA; Brander, DM; Sundaram, S; Seddon, AN; Seymour, E; Patel, M; Martinez-Calle, N; Munir, T; Walewska, R; Broom, A; Walter, H; El-Sharkawi, D; Parry, H; Wilson, MR; Patten, PEM; Hernandez-Rivas, JA; Miras, F; Escalada, NF; Ghione, P; Nabhan, C; Lebowitz, S; Bhavsar, E; Lopez-Jimenez, J; Naya, D; Garcia-Marco, JA; Skanland, SS; Cordoba, R; Eyre, TA

Mato, AR (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.

BLOOD, 2020; 136 (10): 1134

Abstract

Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection a......

Full Text Link